Head to head
InMode vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: INMD · ABT
INMD
InMode
14.00-0.07%
1-year price shape — -7% over the period
Quant Rating C · 60/100
vs
ABT
Abbott Laboratories
98.36-0.37%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
InMode edges it on the scoreable measures. InMode has the highest Quant Rating (60); InMode has done best over the past year (-7%); InMode trades cheapest on trailing earnings.
| INMD | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 14.00 | 98.36 |
| Change today | -0.07% | -0.37% |
| 1-year return | -6.8% | -24.1% |
| Market cap | $805.62M | $170.20B |
| 52-week range | 12.72 – 16.67 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | 11.57 | 31.83 |
| P/E percentile, own 5-yr range | 57th | 62nd |
| P/B | 1.28 | 3.33 |
| Dividend yield | 0.00% | 2.48% |
| Profitability & growth | ||
| EPS (TTM) | 1.43 | 3.72 |
| Net profit (TTM) | $82.29M | $6.44B |
| Revenue (TTM) | $374.63M | $46.59B |
| Revenue growth (YoY) | -0.0% | +13.0% |
| Gross margin | 76.5% | 56.6% |
| Operating margin | 18.5% | 15.8% |
| Net margin | 20.7% | 11.6% |
| Free cash flow (TTM) | $82.53M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 57.9% | 81.2% |
| Insider activity (12mo) | 4 buy / 0 sell | 36 buy / 12 sell |
| Short interest (% of float) | 4.1% | 1.1% |
| Analyst consensus | 100% hold (3) | 100% buy (14) |
| Analyst price target | $17 (+21%) | $125 (+27%) |
| StockVane view | ||
| StockVane Quant Rating | C (60) | E (15) |
| Company | ||
| Employees | 660 | 115,000 |
| Founded | 2008 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.